Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Maria Koehler resigned as Director at ARS Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Powell resigned as Director at ARS Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Vicki L. Capps resigned as Director at ARS Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rajeev Dadoo was appointed as Class I Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
Rajeev Dadoo, Ph.D. 52 Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sarina Tanimoto was appointed as Chief Medical Officer at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
Sarina Tanimoto, M.D., M.B.A. 54 Chief Medical Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brenton L. Saunders was appointed as Class II Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Brenton L. Saunders 52 Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Kolchinsky was appointed as Class II Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Peter Kolchinsky, Ph.D. 46 Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pratik Shah was appointed as Chair of the Board and Class I Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chair of the Board and Class I Director
Exact text from the filing
Pratik Shah, Ph.D. 52 Chair of the Board and Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Russ Hawkinson was terminated as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..
- Action
- terminated
- Role
- Interim Chief Financial Officer
Exact text from the filing
each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Justin Chakma was appointed as Chief Business Officer and Secretary at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chief Business Officer and Secretary
Exact text from the filing
Justin Chakma 33 Chief Business Officer and Secretary
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Hershberg resigned as Director at ARS Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eric Karas was appointed as Chief Commercial Officer at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chief Commercial Officer
Exact text from the filing
Eric Karas 50 Chief Commercial Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Phillip Schneider was appointed as Class III Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
Phillip Schneider 66 Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey Pepe was terminated as Interim Chief Executive Officer, General Counsel and Corporate Secretary at ARS Pharmaceuticals, Inc..
- Action
- terminated
- Role
- Interim Chief Executive Officer, General Counsel and Corporate Secretary
Exact text from the filing
each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jonathan S. Leff was appointed as Class III Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
Jonathan S. Leff 53 Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Lowenthal was appointed as President and Chief Executive Officer at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
Richard Lowenthal, M.S., MSEL 56 President, Chief Executive Officer and Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kathleen Scott was appointed as Chief Financial Officer at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
Kathleen Scott 53 Chief Financial Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jonathan Root resigned as Director at ARS Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Kelly was appointed as Class I Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
Michael Kelly 57 Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Lowenthal was appointed as Class II Director at ARS Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Pursuant to the terms of the Merger Agreement, each of (i) Mr. Lowenthal, Dr. Shah, Dr. Dadoo, Mr. Kelly, Dr. Kolchinsky, Mr. Leff, Mr. Saunders and Mr. Schneider were appointed to the board of directors of the Company as designees of ARS Pharma
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
ARS Pharmaceuticals, Inc.: Silverback Therapeutics, Inc. changed its name to ARS Pharmaceuticals, Inc. via a charter amendment effective upon merger consummation (effective 2022-11-08).
- Change
- charter amendment
- Effective
- 2022-11-08
Exact text from the filing
on November 8, 2022, Silverback filed the Charter Amendment changing its name from "Silverback Therapeutics, Inc." to "ARS Pharmaceuticals, Inc."
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
ARS Pharmaceuticals, Inc. underwent a change of control involving ARS Pharmaceuticals, Inc. (closed 2022-11-08).
- Action
- change of control
- Counterparty
- ARS Pharmaceuticals, Inc.
- Closing
- 2022-11-08
Exact text from the filing
On November 8, 2022, Silverback, Merger Sub and ARS Pharma consummated the transactions contemplated by the Merger Agreement
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.